| Literature DB >> 29775961 |
Azhwar Raghunath1, Kiruthika Sundarraj1, Raju Nagarajan2, Frank Arfuso3, Jinsong Bian4, Alan P Kumar5, Gautam Sethi6, Ekambaram Perumal7.
Abstract
Exposure to antioxidants and xenobiotics triggers the expression of a myriad of genes encoding antioxidant proteins, detoxifying enzymes, and xenobiotic transporters to offer protection against oxidative stress. This articulated universal mechanism is regulated through the cis-acting elements in an array of Nrf2 target genes called antioxidant response elements (AREs), which play a critical role in redox homeostasis. Though the Keap1/Nrf2/ARE system involves many players, AREs hold the key in transcriptional regulation of cytoprotective genes. ARE-mediated reporter constructs have been widely used, including xenobiotics profiling and Nrf2 activator screening. The complexity of AREs is brought by the presence of other regulatory elements within the AREs. The diversity in the ARE sequences not only bring regulatory selectivity of diverse transcription factors, but also confer functional complexity in the Keap1/Nrf2/ARE pathway. The different transcription factors either homodimerize or heterodimerize to bind the AREs. Depending on the nature of partners, they may activate or suppress the transcription. Attention is required for deeper mechanistic understanding of ARE-mediated gene regulation. The computational methods of identification and analysis of AREs are still in their infancy. Investigations are required to know whether epigenetics mechanism plays a role in the regulation of genes mediated through AREs. The polymorphisms in the AREs leading to oxidative stress related diseases are warranted. A thorough understanding of AREs will pave the way for the development of therapeutic agents against cancer, neurodegenerative, cardiovascular, metabolic and other diseases with oxidative stress.Entities:
Keywords: ARE SNPs; ARE-reporter constructs; Antioxidant genes; Antioxidant response elements; Keap1/Nrf2/ARE pathway; Oxidative stress
Mesh:
Substances:
Year: 2018 PMID: 29775961 PMCID: PMC6007815 DOI: 10.1016/j.redox.2018.05.002
Source DB: PubMed Journal: Redox Biol ISSN: 2213-2317 Impact factor: 11.799
The experimentally identified functional AREs in human, mice, rat, zebrafish and cell lines.
| −3118, −291, −330 | MA | Antioxidant | ||||
| −76, −387 | SDM | Antioxidant | ||||
| −3429, −4322 | ChIP, SDM, EMSA | Antioxidant | ||||
| −349 | ChIP, SDM | Antioxidant | ||||
| −416 | EMSA | Antioxidant | ||||
| −301 | EMSA | Antioxidant | ||||
| −1565 | RA, SDM | Metal binding protein | ||||
| −99 | TTA | Metal binding protein | ||||
| −5522 | EMSA, ChIP | Detoxification protein | ||||
| −499 | CL, SA | Detoxification protein | ||||
| −463 | CAT RA, SA | Detoxification protein | ||||
| −3296 | EMSA | Detoxification protein | ||||
| −3231, −3995, −4009, −4073, −4186, −5520, −6047, −6080, −7184, −9059, −9088, −9117, −9146, −9579, −11779 | ChIP | Antioxidant | ||||
| – | ChIP | Microtubule associated protein Tau | ||||
| −2603 to −2629 | EMSA, ChIP | Transcription factor | ||||
| −52, −341 | ChIP | Proteolytic degradation of misfolded proteins | ||||
| −59, −915, −937 | EMSA, FP | Antioxidant | ||||
| −35, −804 | ChIP | Antioxidant | ||||
| −440 | SDM | Antioxidant | ||||
| −4076, −4023 | RA | Metal binding protein | ||||
| −1118 | RA, SDM | Metal binding protein | ||||
| −69 | TTA | Metal binding protein | ||||
| −214 | TTA | Metal binding protein | ||||
| −925 | RA, EMSA | Detoxification protein | ||||
| −728 | EMSA | Detoxification protein | ||||
| −147 | SDM, RA, EMSA | Detoxification protein | ||||
| −94 | RA, EMSA | Excretion pump | ||||
| −435 | SDM, GW, 5’RACE, EMSA | Detoxification protein | ||||
| −126, −3318, −3547, −3612, −3990, −4042, −4090, −6069, −7426, −8709, −9734, −9763, −9791, −9878 | EMSA, SDM | Antioxidant | ||||
| −784 | EMSA, SDM | Anti-inflammation | ||||
| −983 to −944 | EMSA, RA | Catalyzing the reduction of glucose to sorbitol | ||||
| −731 to −722 | RA | Antioxidant | ||||
| −502 to −493 | RA | Antioxidant | ||||
| −913 to −904, −743 to −734, −728 to −719, −148 to −139 | RA | Antioxidant | ||||
| −1762 to −1733 | EMSA, ChIP | Transcription factor | ||||
| −247 | SDM | Antioxidant | ||||
| −696 | MA | Detoxification protein | ||||
| −421 | CAT RA | Detoxification protein | ||||
| −3470 to −3500 | EMSA, ChIP | Transcription factor | ||||
| – | EMSA | Antioxidant | ||||
| −453 to −444, −355 to −346 | RA | Antioxidant | ||||
| −690 to −681 | RA | Antioxidant | ||||
| −749 to –740, −1331 to −1322 | RA | Antioxidant | ||||
| −53 to −45 | EMSA | Antioxidant | ||||
| −86 to −77 | ChIP | Transcription factor | Adenocarcinomic human alveolar basal epithelial cells | |||
| −48 to −62, −46 to −32 | ChIP, EMSA | Antioxidant | Bovine arterial endothelial cells | |||
| −452 to −420 | EMSA | Antioxidant | Erythroleukemic cell line | |||
| −754 | EMSA, ChIP | Transcription factor | Murine keratinocyte cell line | |||
| – | SDM, EMSA, ChIP | Antioxidant | Mouse hepatoma Hepa1c1c7 | |||
| – | EMSA | Antioxidant | Immortalized rat proximal tubular epithelial cells | |||
| −536 to −528, −1429 to −1421 | SDM, ChIP | Antioxidant | Human lung cancer cell line | |||
| −461 to −455 | CAT RA | Anticancer | Human colon adenocarcinoma cell lines | |||
| – | CAT RA, EMSA | Detoxification protein | Human monocyte cell lines | |||
| – | EMSA | Antioxidant | Human breast adenocarcinoma cell line and cervical cancer cell line | |||
| – | EMSA | Transcription factor | Human umbilical vein endothelial cells | |||
| – | EMSA | Antioxidant | Human umbilical vein endothelial cells | |||
| −4117 | EMSA | Antioxidant | Hepatoma cells, Liver hepatoblastoma cell line | |||
| – | EMSA | Transcription factor | Human umbilical vein endothelial cells | |||
| – | EMSA, RA | Excretion pump | Mouse hepatoma cell, human hepatoblastoma cell line | |||
| – | EMSA, RA | Excretion pump | Mouse hepatoma cell, human hepatoblastoma cell line | |||
| −152 to −121, −212 to −183, −78 to −49, −62 to −31 | EMSA | Antioxidant | Mouse embryonic fibroblast | |||
| – | EMSA | Drug metabolizing enzyme | Liver hepatoblastoma cell line | |||
| – | EMSA | Drug metabolizing enzyme | Liver hepatoblastoma cell line | |||
| – | EMSA | Oxidative stress response | Liver hepatoblastoma cell line | |||
| – | EMSA | Oxidative stress response | Liver hepatoblastoma cell line | |||
| −312 | SDM, EMSA | Antioxidant | Liver hepatoblastoma cell line | |||
| – | EMSA | Antioxidant | Rat hepatocyte derived cell line | |||
| – | ChIP | Antioxidant | Human hepatocarcinoma cell line | |||
| – | – | Transcription factor | Human Ovarian carcinoma cell line | |||
| – | EMSA | Transcription factor | Human umbilical |
The experimental methods employed in the identification of AREs abbreviated in this column are as follows: MA, mutational analysis; ChIP, chromatin immunoprecipitation assay; SDM, site directed mutagenesis; EMSA, electrophoretic mobility shift assay; RA, Reporter gene assay; TTA, transient transfection assay; CL, chromosomal localization; SA, sequence analysis; CAT RA, chloramphenicol acetyltransferase reporter assay; FP, foot printing; GW, genome walking; 5'RACE, rapid amplification of 5' complementary DNA ends.
Fig. 3ARE SNPs influence the expression of target genes. The SNPs present in the AREs alter the affinity of the transcription factors towards AREs and modulate the expression of their target genes. The specific allele carried within the AREs may either increase or decrease the risk of disease.
Fig. 1Overview of the transcription factors involved in the activation or repression of target gene expression via AREs. Besides the partners in the dimerization, the transcription factors may either activate or repress the target gene expression based on the nature of cell type, electrophilic compound, oxidative stressor, and target gene.
Fig. 2The different applications based on ARE reporter constructs. The ARE based reporter constructs are used in the bioassay, detection, monitoring, and screening of various compounds/drugs in both in vitro and in vivo models.